Halogenated Derivatives of Aromatic Amino Acids Exhibit Balanced Antiglutamatergic Actions: Potential Applications for the Treatment of Neurological and Neuropsychiatric Disorders

Author(s): Anatoly E. Martynyuk, Christoph N. Seubert, Viktor Yarotskyy, Alexander V. Glushakov, Nikolaus Gravenstein, Colin Sumners, Donn M. Dennis

Journal Name: Recent Patents on CNS Drug Discovery (Discontinued)

Volume 1 , Issue 3 , 2006


Glutamate, the major excitatory neurotransmitter, is critical for normal brain development and function. Both extremes of glutamate receptor activity are detrimental for the brain. Glutamates role in excitotoxicity has driven the search for receptor antagonists as neuroprotective agents, most of which have failed to achieve clinical, i.e. efficacious and safe, neuroprotection. High selectivity and potency provide potential explanations for this failure. For example, targeting individual glutamate receptor subtypes leaves other pathways of glutamatergic excitotoxicity intact. Furthermore, potent depression of glutamate receptor activity causes clinical side effects, such as the symptoms of schizophrenia produced by NMDA receptor antagonists. To produce efficacious neuroprotection devoid of significant side effects, it may be necessary to normalize the function of all components of the glutamatergic system, instead of blocking a single type of glutamate receptors. Halogenated derivatives of aromatic amino acids modulate glutamatergic activity via multiple pre- and postsynaptic actions with moderate efficacy. In addition, these compounds may trap hydroxyl radicals and facilitate hydroxyl radical-impaired glutamate uptake. Their balanced polyvalent action may overcome the limitations of previously tested glutamatergic agents and provide a basis for their use in the treatment of neurological and neuropsychiatric disorders. The properties of this class of compounds and relevant patents are reviewed in this article.

Keywords: Phenylalanine, 3,5-dibromotyrosine, 3,5-dibromo-L-phenylalanine, glutamate, NMDA, AMPA/kainate, stroke, middle cerebral artery occlusion, schizophrenia, phenylketonuria

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [261 - 270]
Pages: 10
DOI: 10.2174/157488906778773706
Price: $58

Article Metrics

PDF: 2